TKP Masthead

Hype Cycle Alert: Play This Biotech Breakout For Big Gains

Welcome to your Hype Cycle Insider report!

Remember, these monthly bonus reports exclusively for Technology Profits Confidential PRO readers pull back the curtain on a stock that's ramping up the innovation curve so that you can act before mainstream investors are paying attention.

Driven by a spate of high-profile buyouts since spring, biotech has been hot! The S&P Biotech ETF, which tracks the biotech sector, has risen 20% since early April. 

Biotech buyouts are driven by Big Pharma greed. Commercial-stage pharmaceutical companies own perishable assets in the form of patent drugs, drugs which can suddenly be worth much less when they come off patent and generic competition hits.

So, besides internal research and development, pharmaceutical companies with enough cash often go out and buy promising junior players—biotechs--with assets either looking like they will succeed in the market, or are already doing so. 

Axsome Therapeutics (NASDAQ: AXSM) could be one of those companies. The $3.69 billion company has been trading in a range all year, but earlier this month started to break out, suggesting higher share prices are in its future.

chart

Investors have good reason to get excited about Axsome. The company has been developing a new drug to treat major depressive disorder. The drug, called AXS-05, targets receptors of the central nervous system. 

AXS-05 is a proprietary formulation consisting of two components. One is dextromethorphan (DM), a common component of cough suppressants. The second is bupropion, an existing antidepressant. The combination drug is formulated in such a way as to inhibit the metabolism of DM, so it can stay in the brain longer, where it can modulate an array of cell receptors and neurotransmitters. Bupropion itself is used to treat depression, where it affects neurotransmitters like dopamine as well as norepinephrine. Combining the two is synergistic, with bupropion increasing the bioavailability of DM.

In Phase 3 trials AXS-05 showed a marked diminution in depressive symptoms, with 53% scoring improvements compared to only 33% on placebo. On another measure, 47% of patients reported feeling much, or very much improved when taking the drug.

Success in this Phase 3 trial sets Axsome up for a new drug application at the FDA, something it plans to do in the fourth quarter of this year. Since AXS-05 has already received Breakthrough Therapy Designation from the FDA, I believe it is highly likely Axsome will see this drug receive priority review, too. Priority means the review and decision on AXS-05’s application would only take 6 months instead of 10 months.

The FDA approved Axsome’s depression treatment last October, and the company is steadily growing sales numbers. But AXS-05 is also in Phase 3 clinical development for Alzheimer’s Disease agitation, as well as a smoking cessation aid. Add to that an additional three drugs in the pipeline. One drug is AXS-07, which the company expects to file for regulatory approval next quarter for migraines. Another, AXS-12, is expected to generate results from a Phase 3 trial in narcolepsy later this month.

But the real shocker is what Axsome believes its drugs will generate in terms of sales. Axsome expects that once approved, its stable of new drugs could pull in up to $11.5 billion, implying a huge upside from its current price. Even analysts' forecasts, which don’t include the sales potential for all of Axsome’s drugs, range up to $4.5 billion per year—still a huge opportunity at current prices. 

That makes this month’s breakout in AXSM shares a great buy opportunity.

Consider buying shares of Axsome Therapeutics (NASDAQ: AXSM)

Important Note: As a reminder, Hype Cycle Insider picks are an exclusive bonus benefit for Technology Profits Confidential PRO readers like you but they aren’t official Tech Profits Confidential recommendations. That means we won't track this stock in our model portfolio. If you choose to buy, plan your entry and exit carefully. Never invest money you can't afford to lose.

Want More Technology Profits Confidential Pro?

Do you like this content? Would you like to know more? Because we have this and much more to share with you. Get started today!

Why “Nvidia Math” Is Going To Make Us Rich

Nvidia’s AI ecosystem of chips and services is expanding into an unstoppable monster, projecting advances to its AI chips that will make the current generation every big AI hyperscaler is clamoring for seem like child’s play. Here’s why the future of AI could not have come at a better time…

Read More

A Political Tour De Force

Donald Trump’s address to a joint session of Congress was a political and historical tour de force as his common sense revolution is impacting America. Jim reviews the speech in this special report.

Read More

RIP ChatGPT

President Trump and Elon Musk have already taken giant steps to make America the center of the AI revolution. But Musk's xAI just dropped a bombshell that could rewrite the AI playbook. Check it out…

Read More

The Manifest Destiny Into the Stars

As Trump calls for a new Manifest Destiny in space, America faces the opposition of two forces: the economic realities of today’s globalized market and the unpredictable, high-risk gamble of space exploration. This tension between speculative ambition and practicality has seeped into the markets as well.

Read More

Still Sticky

With inflation rising again in January, the Fed will likely keep rates unchanged for the foreseeable future. Jay Powell doesn’t seem in any hurry to take further action. Read Jim’s special report for insight into the Fed’s data dependency and why following markets instead of leading could spell trouble for the economy and your investments.

Read More

A Common Sense Strategy For The Current Market

Zach reveals a common sense strategy for extra income.

Read More

shutterstock 2269078915

Will Deportation Hurt The Economy?

This week, Jim answers questions on American manufacturing, silver as an investment, and immigration’s impact on the economy.

Read More

The Hidden Genius of the “AiPhone”

Today, let’s look at the big new challenge facing AI companies. Hint: It’s not just about chip performance anymore…

Read More

2025: The Year Enterprise Finally Embraces AI

A new breed of AI is emerging that will be a game-changer for big business. Here’s why we’re set to profit from this trend…

Read More

FED RECAP: The Markets Lead the Fed

With a third cut this year, the Fed continues to follow the employment part of its dual mandate. But inflation is starting to muddy up the waters. Read Jim’s special report in full for insight on the Fed’s dilemma as we move into a new year and why the central bank’s reacting to data instead of being proactive is bad news for investors.

Read More